Association Between ALDH2 Gene Polymorphism and Atrial Fibrillation
AAAF
1 other identifier
observational
200
1 country
1
Brief Summary
This study is a case-control study. In this study, 2ml of vein blood samples were collected from patients with atrial fibrillation undergoing radiofrequency ablation and those in the control group who underwent electrophysiological examination alone and confirmed no arrhythmia. The purpose of this study is to identify the relationship between the aldehyde dehydrogenase 2 (ALDH2) gene polymorphism and susceptibility to atrial fibrillation, and to explore the relationship between the genotype of ALDH2 SNP and the prognosis of patients with atrial fibrillation undergoing radiofrequency ablation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 20, 2022
CompletedFirst Submitted
Initial submission to the registry
August 30, 2022
CompletedFirst Posted
Study publicly available on registry
September 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2024
CompletedSeptember 1, 2022
August 1, 2022
1.6 years
August 30, 2022
August 30, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
atrial fibrillation recurrence
atrial fibrillation recurrence
3 months
Study Arms (2)
Atrial fibrillation
Patients with atrial fibrillation underwent radiofrequency ablation.
Control
Patients underwent electrophysiological examination alone and were confirmed no arrhythmia.
Eligibility Criteria
Consecutive patients diagnosed with atrial fibrillation in the Second Affiliated Hospital of Zhejiang University School of Medicine.
You may qualify if:
- Signed informed consent;
- Age 18-85 years old, gender is not limited; ③ Case group: patients with clinical diagnosis of atrial fibrillation who underwent radiofrequency ablation; control group: patients with no arrhythmia confirmed by electrophysiological examination; ④ Able to communicate well with investigators and comply with the entire trial requirements.
You may not qualify if:
- Those who cannot understand or refuse to sign the informed consent or follow-up; ②Pregnant women, mentally retarded, mental/cognitive insufficiency and other possible vulnerable groups
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
Related Publications (1)
Jin J, Qian N, Gao Y, Liu J, Chen D, Wang B, Luo M, Zhang Y, Ye J, Jiang R, Wang L, Jiang J, Wang Y. Diabetes and ALDH2 Gene Polymorphism on Post-Ablation Atrial Fibrillation Recurrence. JACC Asia. 2025 Nov 12:S2772-3747(25)00638-6. doi: 10.1016/j.jacasi.2025.10.021. Online ahead of print.
PMID: 41342828DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 30, 2022
First Posted
September 1, 2022
Study Start
May 20, 2022
Primary Completion
December 31, 2023
Study Completion
June 30, 2024
Last Updated
September 1, 2022
Record last verified: 2022-08